Massachusetts Financial Services Co. MA Trims Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Massachusetts Financial Services Co. MA lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 5.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,379 shares of the medical equipment provider’s stock after selling 1,500 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Hologic were worth $2,107,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Cetera Investment Advisers raised its position in shares of Hologic by 188.9% in the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after buying an additional 13,380 shares during the last quarter. Nordea Investment Management AB raised its holdings in Hologic by 1.3% in the 1st quarter. Nordea Investment Management AB now owns 1,507,743 shares of the medical equipment provider’s stock valued at $116,797,000 after acquiring an additional 19,680 shares during the last quarter. Pinebridge Investments L.P. lifted its stake in shares of Hologic by 39.8% during the 4th quarter. Pinebridge Investments L.P. now owns 397,251 shares of the medical equipment provider’s stock worth $28,384,000 after purchasing an additional 113,050 shares during the period. Clearbridge Investments LLC boosted its holdings in shares of Hologic by 51.4% during the first quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock worth $40,430,000 after purchasing an additional 176,006 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Hologic by 18.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,184,427 shares of the medical equipment provider’s stock valued at $170,297,000 after purchasing an additional 338,212 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Performance

HOLX stock opened at $81.39 on Monday. The firm has a market cap of $18.99 billion, a P/E ratio of 41.53, a P/E/G ratio of 2.53 and a beta of 0.98. The stock’s 50 day simple moving average is $80.82 and its 200 day simple moving average is $77.13. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the firm earned $0.93 EPS. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. As a group, equities research analysts predict that Hologic, Inc. will post 4.09 EPS for the current year.

Insider Buying and Selling

In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the transaction, the insider now directly owns 10,476 shares in the company, valued at approximately $858,927.24. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the transaction, the insider now owns 10,476 shares in the company, valued at approximately $858,927.24. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares in the company, valued at approximately $310,415.85. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,280 shares of company stock valued at $1,469,973. Insiders own 1.75% of the company’s stock.

Analyst Ratings Changes

HOLX has been the topic of several recent analyst reports. StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 18th. Stephens reissued an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research report on Tuesday, July 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Tuesday, September 17th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a report on Friday, August 16th. Finally, JPMorgan Chase & Co. upped their price objective on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $87.60.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.